FDA launches pilot to experiment with common, global submission format

In a bid for regulatory convergence with other international regulators, the FDA announced it is looking for companies to participate in a pilot program involving the use of a common international format for regulatory submissions like 510(k)s and PMAs.

The move marks the first step toward a common format that would be used by all U.S. manufacturers.

The pilot was launched in collaboration with the International Medical Device Regulators Forum, whose members include the device regulators of Australia (Therapeutic Goods Administration), Brazil (ANVISA), Canada (Health Canada), China (China Food and Drug Administration), and the European Union (Notified Bodies).

To participate in the program, companies must be making submissions to both the FDA and the aforementioned IMDRF members who are also interested in the common submission format. The common format will be defined by a table of contents.

"The ToC provides a comprehensive submission structure that can be used as a harmonized international electronic submission format while minimizing regional divergences and indicating where regional variation exists," the FDA writes in the Federal Register.

Submission contents will not be shared with other regulators or manufacturers, but feedback about the common format will be shared among IMDRF regulators in order to evaluate and improve the usability of the table of contents.

In 2014, IMDRF members agreed to a common format for non-in vitro diagnostic submissions. The new pilot is a step toward a universal common submission format for other devices as well, in the hopes that it will make life easier for companies trying to sell equipment in various countries.

The agency says participation in the program will "provide both local and international benefits for FDA, as it will provide FDA feedback into decisions regarding the ToC's suitability."

Up to 9 companies can enroll in the pilot program, which lasts from September 2015 to 2016.

- read more in the Federal Register

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.